Methods of treating dry eye syndrome
AssigneeRegentree, LLC
InventorsWon Suk Yang, Sin Wook Kang, Kyoungsun Kim
Life of this patent
Estimating the term…
Abstract
Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (Tβ4), Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.
Claims22
A method of increasing tear amounts in a subject in need thereof, wherein the method comprises delivering a composition containing thymosin beta 4 (Tβ4), Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof to an affected eye of the subject.
A method of increasing tear film stability in a subject in need thereof, wherein the method comprises delivering a composition containing Tβ4, Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof to an affected eye of the subject.
A method of decreasing ocular surface damage in a subject in need thereof, wherein the method comprises delivering a composition containing Tβ4, Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof to an affected eye of the subject.
A method of decreasing ocular discomfort in a subject in need thereof, wherein the method comprises delivering a composition containing Tβ4, Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof to an affected eye of the subject.
A method of treating DES in a subject in need thereof, wherein the method comprises delivering a composition containing Tβ4, Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof to an affected eye of the subject, wherein the DES is characterized by decreased tear amount, decreased tear film stability, increased ocular surface damage, increased ocular discomfort, or combinations thereof.
(canceled)
An ophthalmic composition comprising an effective amount of Tβ4, Tβ4 fragments, Tβ4 isoforms, Tβ4 derivatives, peptide agents including amino acid sequence LKKTET or LKKTNT, or variants thereof or use in a method for treating DES in a subject in need thereof, wherein the DES is characterized by decreased tear amount, decreased tear film stability, increased ocular surface damage, increased ocular discomfort, and combinations thereof.
Dependencies are inferred from the claim text.